VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry

SARS-CoV-2 infection of host cells starts by binding the Spike glycoprotein (S) to the ACE2 receptor. The S-ACE2 interaction is a potential target for therapies against COVID-19 as demonstrated by the development of immunotherapies blocking this interaction. VE607 — a commercially available compound...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Shilei, Ullah, Irfan, Gong, Shang Yu, Grover, Jonathan R., Mohammadi, Mohammadjavad, Chen, Yaozong, Vézina, Dani, Beaudoin-Bussières, Guillaume, Verma, Vijay Tailor, Goyette, Guillaume, Gaudette, Fleur, Richard, Jonathan, Yang, Derek, Smith, Amos B., Pazgier, Marzena, Côté, Marceline, Abrams, Cameron, Kumar, Priti, Mothes, Walther, Uchil, Pradeep D., Finzi, Andrés, Baron, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164512/
https://www.ncbi.nlm.nih.gov/pubmed/35677392
http://dx.doi.org/10.1016/j.isci.2022.104528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164512/
https://www.ncbi.nlm.nih.gov/pubmed/35677392
http://dx.doi.org/10.1016/j.isci.2022.104528

Ejemplares similares